Clinical trial
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555…
NCT00150228 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00150228 |
|---|---|
| Title | 12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation |
| Official title | A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Drug |
| Interventions | CP-526, 555 (varenicline) |
| Enrollment | 300 |
| Start date | Dec 1, 2001 |
| Completion | Sep 1, 2002 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 4, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: